london euretina

This meeting has been awarded 20 CME credits

Security Notice

Please note that Kuoni are our only destination management company. Other venders indicating that are operating for the society should be ignored. We never use western union as a payment portal

Posters

Ranibizumab for the treatment of macular edema secondary to retinal vein occlusion – a six month follow-up

Poster Details

First Author: I.Karska-Basta POLAND

Co Author(s):    A. Kubicka-Trząska   P. Oleksy   B. Romanowska-Dixon            0   0 0   0 0   0 0   0 0

Abstract Details



Purpose:

To determine the effectiveness of treatment for macular edema (ME) secondary to retinal vein occlusion (RVO) with intravitreal injections (IVIs) of ranibizumab.

Setting:

RVO remains second only to diabetic retinopathy as the most common retinal vascular disorder. The treatment for the associated macular edema - a major cause of vision loss - has always been challenging.

Methods:

The study included 6 eyes affected with macular edema (ME) due to retinal vein occlusion (RVO). There were 5 males and 1 female at the age of 49 to 62 years (mean age 61). The baseline ophthalmic examination included best corrected visual acuity (BCVA), slit lamp biomicroscopy, fundoscopy, fluorescein angiography (FA), and optical coherence tomography (OCT). Three eyes were diagnosed for central retinal vein occlusion (CRVO) and 3 eyes for branch retinal vein occlusion (BRVO). Follow-up were performed monthly and was the same as the baseline examination, except for angiography. Four patients were treated with intravitreal injections (IVI) of ranibizumab 0.5mg alone and in 2 cases the additional grid laser was performed. The IVIs were performed every four weeks during the first three months and then the decision concerning reinjection was based on the results of BCVA and OCT. Grid laser was administered at 4th week in 2 eyes if criteria for laser treatment were met. The follow-up period was 6 months.

Results:

All of the patients showed improvement in BCVA and central foveal thickness (CFT). During a follow-up period the BCVA went from a median of 54.5 to 70.0 letters in patients treated with ranibizumab alone and from 71.0 to 86.5 in patients treated with ranibizumab and laser. The values for CFT changed from a median of 609 micrometer to 287. The treatment reaches maximum effectiveness after three months of therapy, and remained constant until the end of 6th month.

Conclusions:

The results of our study indicate that IVIs of ranibizumab is a novel, preserving vision method of treatment for ME due to RVO.

Back to previous
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email: euretina@euretina.org

Privacy policyHotel Terms and Conditions Cancellation policy